Table 2.

Frequency and severity of adverse events that where possibly, probably, or definitely related to SU5416 administration in patients who received at least one dose (n = 42) and seen in less than 5% of study patients



Number of patients experiencing events (%)
Adverse event
Grades 1 + 2
Grades 3 + 4
Total
All events   31 (74)   19 (45)   34 (81)  
Bone/muscoloskeletal pain   13 (31)   3 (7)   13 (31)  
Nausea   13 (31)   1 (2)   13 (31)  
Headache   11 (26)   1 (7)   11 (26)  
Insomnia   10 (24)   0   10 (24)  
Vomiting   7 (17)   0   7 (17)  
Fatigue/malaise   5 (12)   3 (7)   5 (12)  
Vertigo   5 (12)   0   5 (12)  
Abdominal pain   4 (10)   0   4 (10)  
Diaphoresis   4 (10)   0   4 (10)  
Chest pain   3 (7)   1 (2)   4 (10)  
Hypokalemia   3 (7)   0   3 (7)  
Implant infection   2 (5)   1 (2)   3 (7)  
Sepsis
 
0
 
3 (7)
 
3 (7)
 


Number of patients experiencing events (%)
Adverse event
Grades 1 + 2
Grades 3 + 4
Total
All events   31 (74)   19 (45)   34 (81)  
Bone/muscoloskeletal pain   13 (31)   3 (7)   13 (31)  
Nausea   13 (31)   1 (2)   13 (31)  
Headache   11 (26)   1 (7)   11 (26)  
Insomnia   10 (24)   0   10 (24)  
Vomiting   7 (17)   0   7 (17)  
Fatigue/malaise   5 (12)   3 (7)   5 (12)  
Vertigo   5 (12)   0   5 (12)  
Abdominal pain   4 (10)   0   4 (10)  
Diaphoresis   4 (10)   0   4 (10)  
Chest pain   3 (7)   1 (2)   4 (10)  
Hypokalemia   3 (7)   0   3 (7)  
Implant infection   2 (5)   1 (2)   3 (7)  
Sepsis
 
0
 
3 (7)
 
3 (7)
 
Close Modal

or Create an Account

Close Modal
Close Modal